{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-133637","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.289077+00:00","generated_at":"2026-06-28T13:48:09.252873+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Protagonist Q3 net loss $33.8M; rusfertide hold lifted, PN-235 advancing to Phase 2","bullets":["Net loss $33.8M ($0.70/share) vs $7.8M loss in Q3 2020; revenue $10.3M (incl. $8M catch-up from Janssen amendment).","Cash $352.5M; expects to fund operations through 2024.","FDA removed clinical hold on rusfertide; Phase 3 in PV planned Q1 2022; Zealand agreement cut future milestones/royalties by 50%.","PN-943 Phase 2 IDEAL study enrollment steady; topline data from 12-week induction expected Q2 2022.","IL-23: PN-235 Phase 2 psoriasis starts early 2022; $7.5M milestone from Janssen; up to ~$900M in potential milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-133637","json":"https://secwatch.observer/filing/0001104659-21-133637.json","markdown":"https://secwatch.observer/filing/0001104659-21-133637.md","text":"https://secwatch.observer/filing/0001104659-21-133637.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465921133637/0001104659-21-133637-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465921133637/tm2131730d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T13:48:09.252873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}